Central injection of interleukin-13 potentiates LPS-induced sickness behavior in rats

Systemic administration of the bacterial endotoxin lipopolysaccharide (LPS) has profound depressive effects on behavior that are mediated by the inducible expression of proinflammatory cytokines such as interleukin-1 (IL-1), IL-6 and tumor necrosis factor-α (TNF-α) in the brain. To assess the regulatory effects of the anti-inflammatory cytokine IL-13 on LPS-induced sickness behavior, rats injected i.p. with LPS were administered rat recombinant IL-13 i.c.v. IL-13 (300 ng) potentiated the behavioral effects of LPS (125 μg/kg) when both molecules were co-injected. Administration of IL-13 (300 ng) 12 h prior to LPS (150 μg/kg) did not block the depressing effects of LPS on social exploration. These results indicate that IL-13 acts as a proinflammatory cytokine in the brain.

[1]  F. Cunha,et al.  Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. , 2001, European cytokine network.

[2]  R. Puri,et al.  The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. , 2001, Blood.

[3]  Y. Pollak,et al.  Effects of Antidepressant Drugs on the Behavioral and Physiological Responses to Lipopolysaccharide (LPS) in Rodents , 2001, Neuropsychopharmacology.

[4]  S. Vigues,et al.  Rat interleukin-10: production and characterisation of biologically active protein in a recombinant bacterial expression system. , 2001, European cytokine network.

[5]  R. Dantzer.  Cytokine-Induced Sickness Behavior: Where Do We Stand? , 2001, Brain, Behavior, and Immunity.

[6]  C. Plata-salamán,et al.  Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide , 2001, Brain Research Bulletin.

[7]  A. M. Szczepanik,et al.  IL-4, IL-10 and IL-13 modulate Aβ(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line , 2001, Journal of Neuroimmunology.

[8]  Mushfiquddin Khan,et al.  Interleukin‐10 and Interleukin‐13 Inhibit Proinflammatory Cytokine‐Induced Ceramide Production Through the Activation of Phosphatidylinositol 3‐Kinase , 2000, Journal of neurochemistry.

[9]  P. Rothman,et al.  IL-4/IL-13 signaling beyond JAK/STAT. , 2000, The Journal of allergy and clinical immunology.

[10]  W. Debinski,et al.  Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen , 2000, Molecular medicine.

[11]  R. Puri,et al.  Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. , 2000, Cancer research.

[12]  J. Schrader,et al.  Characterization of the Cytoplasmic Domain of Interleukin-13 Receptor-α* , 1999, The Journal of Biological Chemistry.

[13]  R. Dantzer,et al.  Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats , 1999, Psychoneuroendocrinology.

[14]  C. Ball,et al.  Rat interleukin 6: expression in recombinant Escherichia coli, purification and development of a novel ELISA. , 1999, Cytokine.

[15]  A. Mantovani,et al.  IL-13 inhibits TNF production but potentiates that of IL-6 in vivo and ex vivo in mice. , 1997, Journal of immunology.

[16]  F. Nicoletti,et al.  Prevention of endotoxin‐induced lethality in neonatal mice by interleukin‐13 , 1997, European journal of immunology.

[17]  D. Cockayne,et al.  IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. , 1997, Journal of immunology.

[18]  J. Licinio,et al.  Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Weller,et al.  Maturation‐dependent Modulation of Apoptosis in Cultured Cerebellar Granule Neurons by Cytokines and Neurotrophins , 1996, The European journal of neuroscience.

[20]  M. Tardieu,et al.  Interleukin-13 and interleukin-4 act as interleukin-6 inducers in human microglial cells. , 1996, Cytokine.

[21]  J. Lélias,et al.  Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain* , 1996, The Journal of Biological Chemistry.

[22]  J. G. Zhang,et al.  Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Paul,et al.  Interleukin 4 signals through two related pathways. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Harold Ellis,et al.  Atlas of the Developing Rat Nervous System. , 1995 .

[25]  M. Welham,et al.  Interleukin-13 Signal Transduction in Lymphohemopoietic Cells , 1995, The Journal of Biological Chemistry.

[26]  A. Duschl,et al.  Both Interleukin 4 and Interleukin 13 Induce Tyrosine Phosphorylation of the 140-kDa Subunit of the Interleukin 4 Receptor (*) , 1995, The Journal of Biological Chemistry.

[27]  N. Hamasaki,et al.  Localization of human interleukin 13 receptor in non-haematopoietic cells. , 2001, Cytokine.

[28]  J. Banchereau,et al.  Interleukin-4 and interleukin-13: their similarities and discrepancies. , 1998, International reviews of immunology.